Number of women needed in a prospective trial to prove potential cardiovascular benefit of hormone replacement therapy

References

• Hulley S, Furburg C, Barrett-Connor E, , HERS Research Group, et al. Vascular disease outcomes during 6.8 years of hormone therapy. JAMA 2002; 288: 58–66
   PubMed Web of Science ®Google Scholar
• Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 49–57
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women's Health Initiative. Principal results form the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• Anderson G L, Limacher M, Assaf A R, , Women's Health Initiative Steering Committee, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–1712
   PubMed Web of Science ®Google Scholar
• Stampfer M J, Colditz G A, Willett W C, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991; 325: 756–762
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer M, Colditz G, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769–1775
   PubMed Web of Science ®Google Scholar
• Clarkson T B. The new conundrum: do estrogens have any cardiovascular benefits?. Int J Fertil 2002; 47: 61–68
   Google Scholar
• Stampfer M, Colditz G. Estrogen replacement therapy and coronary disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47–63
   PubMed Web of Science ®Google Scholar
• Hu F, Stampfer M, Manson J, et al. Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. N Engl J Med 2000; 343: 530–537
   PubMed Web of Science ®Google Scholar
• Manson J E, Hsia J, Johnson K C, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523–534
   PubMed Web of Science ®Google Scholar
• Naftolin F, Taylor H, Karas R, et al. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 2004; 81: 1498–1501
   PubMed Web of Science ®Google Scholar
• Bath Ph, Gray L. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ 2005; 330: 342–344
   PubMed Web of Science ®Google Scholar
• International Menopause Society Executive Committee. Guidelines for the hormone treatment of women in the menopausal transition and beyond: Position Statement by the Executive Committee of the International Menopause Society. Climacteric 2004; 7: 8–11
   PubMed Web of Science ®Google Scholar
• Hsia J, Langer R D, Manson J E, , for the Women's Health Initiative Investigators, et al. Conjugated equine estrogens and coronary heart disease. Arch Intern Med 2006; 166: 357–365
   PubMed Web of Science ®Google Scholar
• Salpeter S, Walsh J, Greyber E, et al. Mortality associated with hormone replacement therapy in younger and older women. J Gen Intern Med 2004; 19: 791–804
   PubMed Web of Science ®Google Scholar
• De Backer G. Nutrition and health: an interuniversity study. Regional differences in dietary habits, coronary risk factors and mortality rates in Belgium. I. Design and methodology. Acta Cardiol 1984; 39: 285–292
   PubMed Web of Science ®Google Scholar
• WHO-MONICA Project Principal Investigators. The World Health Organisation MONICA project (Monitoring Trends and Determinants in Cardiovascular Disease): a major international collaboration. J Clin Epidemiol 1988; 41: 105–114
   PubMed Web of Science ®Google Scholar
• Houtman I, Kornitzer M, De Smet P, et al. Job stress, absenteeism and coronary heart disease: European cooperative study (the JACE study). Design of a multicentre prospective study. Eur J Publ Health 1999; 9: 52–57
   Web of Science ®Google Scholar
• De Backer G, De Bacquer D, Brohet C, et al. Guidelines on cardiovascular disease prevention in clinical practice. Rev Med Liege 2005; 60: 163–172
   PubMedGoogle Scholar
• Braunwald E. Shattuck Lecture – cardiovascular medicine at the turn of the millennium: triumphs, concerns and opportunities. N Engl J Med 1997; 337: 1360–1369
   PubMed Web of Science ®Google Scholar
• Machin D, Campell M J, Fayers P, Pinol A. Statistical Tables for the Design of Clinical Studies2nd edn. Blackwell Publications, Oxford 1997
   Google Scholar
• Tunstall-Pedoe H. Myth and paradox of coronary risk and menopause. Lancet 1998; 351: 1425–1427
   PubMed Web of Science ®Google Scholar
• Raza J A, Reinhart R, Mohaved A. Ischemic heart disease in women and the role of hormone therapy. Int J Cardiol 2004; 96: 7–19
   PubMed Web of Science ®Google Scholar
• Andersen K, Launer L, Dewey M, et al. for the EURODEM Incidence Research Group. Gender differences in the incidence of AD and vascular dementia: the EURODEM studies. Neurology 1999; 53: 1992–1997
   PubMed Web of Science ®Google Scholar
• Zandi P, Carlson M, Plassman B, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women. JAMA 2002; 288: 2123–2129
   PubMed Web of Science ®Google Scholar
• Espeland M, Rapp S, Shumaker S, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women. JAMA 2004; 291: 2959–2968
   PubMed Web of Science ®Google Scholar
• Prestwood K M, Kenny A M, Kleppinger A, et al. Ultralow-dose micronized 17 beta estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA 2003; 290: 1042–1048
   PubMed Web of Science ®Google Scholar
• Viscoli C, Brass L, Kernan W, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001; 345: 1243–1249
   PubMed Web of Science ®Google Scholar
• Hodis H, Mack W, Lobo R. Estrogen in the prevention of atherosclerosis. Ann Intern Med 2001; 135: 939–953
   PubMed Web of Science ®Google Scholar
• Hodis H, Wendy J, Azen S, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003; 349: 535–545
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson J, Colditz G, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933–941
   PubMed Web of Science ®Google Scholar